Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil

Pasquale Comella, Giuseppe Palmieri, Gerardo Beneduce, Rossana Casaretti, Antonio Daponte, Adriano Gravina, Giuseppe Frasci, Edoardo Biondi, Giuseppe Comella

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Twenty-one patients affected by advanced carcinoma of the digestive tract, all but 2 previously treated, received on day 1 every 2 weeks a 2-hour intravenous (i.v.) infusion of methotrexate (MTX), 250 mg/m2, followed 24 h later by a 2-hour i.v. infusion of L-folinic acid (LFA), 250 mg/m2, and 5-fluorouracil (FU), 600 mg/m2 as an i.v. bolus. Only 1 previously untreated patient obtained a partial response. The MTX serum level assessed 24 h after its infusion (24-hour sMTX) ranged from 0.3 to 5.7 (median: 0.9) μM and in only 8/21 patients reached a concentration ≥ 1 μM. A further 46 patients (of whom 22 had been previously treated) received the same treatment as above but with a double dosage (500 mg/m2) of MTX. Twelve of these 46 patients (26%, 95% confidence interval = 14-41%) achieved a partial response with this regimen. Responses were obtained in chemotherapy-naive patients (8/24) and in previously treated patients (4/22). The 24-hour sMTX ranged from 1.2 to 9.5 μM) (median: 2.3) and was ≥ 2 μM in 30/46 patients. Among patients showing a 24-hour sMTX value ≥ 2 μM, the response rate was 39% (45% in previously untreated patients), while no patient with a 24-hour sMTX value below 2 μM at 24 h obtained a major response (p = 0.0017). Our findings demonstrate that 500 mg/m2 of MTX given as a 2-hour i.v. infusion is required to reach a serum concentration of at least 1 μM for 24 h. Furthermore, the double biochemical modulation of FU may obtain an objective response in patients previously treated with fluoropyrimidines.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalOncology
Volume53
Issue number3
Publication statusPublished - May 1996

Fingerprint

Leucovorin
Methotrexate
Fluorouracil
Serum
Neoplasms
Intravenous Infusions
Gastrointestinal Tract
Confidence Intervals

Keywords

  • 5-fluorouracil
  • Biochemical modulation
  • Gastrointestinal carcinoma
  • Methotrexate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil. / Comella, Pasquale; Palmieri, Giuseppe; Beneduce, Gerardo; Casaretti, Rossana; Daponte, Antonio; Gravina, Adriano; Frasci, Giuseppe; Biondi, Edoardo; Comella, Giuseppe.

In: Oncology, Vol. 53, No. 3, 05.1996, p. 198-203.

Research output: Contribution to journalArticle

@article{a1b3842a04134657b0f172a3c5b75c07,
title = "Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil",
abstract = "Twenty-one patients affected by advanced carcinoma of the digestive tract, all but 2 previously treated, received on day 1 every 2 weeks a 2-hour intravenous (i.v.) infusion of methotrexate (MTX), 250 mg/m2, followed 24 h later by a 2-hour i.v. infusion of L-folinic acid (LFA), 250 mg/m2, and 5-fluorouracil (FU), 600 mg/m2 as an i.v. bolus. Only 1 previously untreated patient obtained a partial response. The MTX serum level assessed 24 h after its infusion (24-hour sMTX) ranged from 0.3 to 5.7 (median: 0.9) μM and in only 8/21 patients reached a concentration ≥ 1 μM. A further 46 patients (of whom 22 had been previously treated) received the same treatment as above but with a double dosage (500 mg/m2) of MTX. Twelve of these 46 patients (26{\%}, 95{\%} confidence interval = 14-41{\%}) achieved a partial response with this regimen. Responses were obtained in chemotherapy-naive patients (8/24) and in previously treated patients (4/22). The 24-hour sMTX ranged from 1.2 to 9.5 μM) (median: 2.3) and was ≥ 2 μM in 30/46 patients. Among patients showing a 24-hour sMTX value ≥ 2 μM, the response rate was 39{\%} (45{\%} in previously untreated patients), while no patient with a 24-hour sMTX value below 2 μM at 24 h obtained a major response (p = 0.0017). Our findings demonstrate that 500 mg/m2 of MTX given as a 2-hour i.v. infusion is required to reach a serum concentration of at least 1 μM for 24 h. Furthermore, the double biochemical modulation of FU may obtain an objective response in patients previously treated with fluoropyrimidines.",
keywords = "5-fluorouracil, Biochemical modulation, Gastrointestinal carcinoma, Methotrexate",
author = "Pasquale Comella and Giuseppe Palmieri and Gerardo Beneduce and Rossana Casaretti and Antonio Daponte and Adriano Gravina and Giuseppe Frasci and Edoardo Biondi and Giuseppe Comella",
year = "1996",
month = "5",
language = "English",
volume = "53",
pages = "198--203",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil

AU - Comella, Pasquale

AU - Palmieri, Giuseppe

AU - Beneduce, Gerardo

AU - Casaretti, Rossana

AU - Daponte, Antonio

AU - Gravina, Adriano

AU - Frasci, Giuseppe

AU - Biondi, Edoardo

AU - Comella, Giuseppe

PY - 1996/5

Y1 - 1996/5

N2 - Twenty-one patients affected by advanced carcinoma of the digestive tract, all but 2 previously treated, received on day 1 every 2 weeks a 2-hour intravenous (i.v.) infusion of methotrexate (MTX), 250 mg/m2, followed 24 h later by a 2-hour i.v. infusion of L-folinic acid (LFA), 250 mg/m2, and 5-fluorouracil (FU), 600 mg/m2 as an i.v. bolus. Only 1 previously untreated patient obtained a partial response. The MTX serum level assessed 24 h after its infusion (24-hour sMTX) ranged from 0.3 to 5.7 (median: 0.9) μM and in only 8/21 patients reached a concentration ≥ 1 μM. A further 46 patients (of whom 22 had been previously treated) received the same treatment as above but with a double dosage (500 mg/m2) of MTX. Twelve of these 46 patients (26%, 95% confidence interval = 14-41%) achieved a partial response with this regimen. Responses were obtained in chemotherapy-naive patients (8/24) and in previously treated patients (4/22). The 24-hour sMTX ranged from 1.2 to 9.5 μM) (median: 2.3) and was ≥ 2 μM in 30/46 patients. Among patients showing a 24-hour sMTX value ≥ 2 μM, the response rate was 39% (45% in previously untreated patients), while no patient with a 24-hour sMTX value below 2 μM at 24 h obtained a major response (p = 0.0017). Our findings demonstrate that 500 mg/m2 of MTX given as a 2-hour i.v. infusion is required to reach a serum concentration of at least 1 μM for 24 h. Furthermore, the double biochemical modulation of FU may obtain an objective response in patients previously treated with fluoropyrimidines.

AB - Twenty-one patients affected by advanced carcinoma of the digestive tract, all but 2 previously treated, received on day 1 every 2 weeks a 2-hour intravenous (i.v.) infusion of methotrexate (MTX), 250 mg/m2, followed 24 h later by a 2-hour i.v. infusion of L-folinic acid (LFA), 250 mg/m2, and 5-fluorouracil (FU), 600 mg/m2 as an i.v. bolus. Only 1 previously untreated patient obtained a partial response. The MTX serum level assessed 24 h after its infusion (24-hour sMTX) ranged from 0.3 to 5.7 (median: 0.9) μM and in only 8/21 patients reached a concentration ≥ 1 μM. A further 46 patients (of whom 22 had been previously treated) received the same treatment as above but with a double dosage (500 mg/m2) of MTX. Twelve of these 46 patients (26%, 95% confidence interval = 14-41%) achieved a partial response with this regimen. Responses were obtained in chemotherapy-naive patients (8/24) and in previously treated patients (4/22). The 24-hour sMTX ranged from 1.2 to 9.5 μM) (median: 2.3) and was ≥ 2 μM in 30/46 patients. Among patients showing a 24-hour sMTX value ≥ 2 μM, the response rate was 39% (45% in previously untreated patients), while no patient with a 24-hour sMTX value below 2 μM at 24 h obtained a major response (p = 0.0017). Our findings demonstrate that 500 mg/m2 of MTX given as a 2-hour i.v. infusion is required to reach a serum concentration of at least 1 μM for 24 h. Furthermore, the double biochemical modulation of FU may obtain an objective response in patients previously treated with fluoropyrimidines.

KW - 5-fluorouracil

KW - Biochemical modulation

KW - Gastrointestinal carcinoma

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0029881561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029881561&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 198

EP - 203

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -